STERIS (NYSE:STE) CFO Karen Burton Sells 5,880 Shares of Stock

STERIS plc (NYSE:STE) CFO Karen Burton sold 5,880 shares of the business’s stock in a transaction that occurred on Wednesday, November 11th. The stock was sold at an average price of $255.62, for a total value of $1,503,045.60. Following the completion of the sale, the chief financial officer owned 12,956 shares of the company’s stock, valued at approximately $3,311,812.72. This trade represents a 31.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

STERIS Trading Down 1.1%

Shares of STE stock opened at $253.50 on Friday. STERIS plc has a 12 month low of $195.14 and a 12 month high of $269.44. The company has a quick ratio of 1.44, a current ratio of 2.05 and a debt-to-equity ratio of 0.23. The business’s 50 day moving average is $222.55 and its two-hundred day moving average is $224.61. The company has a market cap of $24.62 billion, a PE ratio of 30.07 and a beta of 0.86.

STERIS (NYSE:STE) last released its quarterly earnings results on Wednesday, November 4th. The medical equipment provider reported $2.94 EPS for the quarter, beating analysts’ consensus estimates of $2.68 by $0.26. STERIS had a net margin of 13.41% and a return on equity of 14.80%. The company had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.56 billion. The company’s quarterly revenue was up 8.8% compared to the same quarter last year. During the same quarter last year, the firm posted $2.47 earnings per share. Equities analysts predict that STERIS plc will post 11.46 EPS for the current year.

STERIS Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 17th. Investors of record on Tuesday, November 17th will be issued a $0.69 dividend. This represents a $2.76 annualized dividend and a yield of 1.1%. The ex-dividend date is Tuesday, November 17th. STERIS’s dividend payout ratio (DPR) is 32.74%.

Hedge Funds Weigh In On STERIS

A number of institutional investors and hedge funds have recently bought and sold shares of STE. Western Wealth Management LLC acquired a new stake in STERIS in the 1st quarter worth $25,000. Compass Financial Management LLC bought a new position in shares of STERIS during the 3rd quarter worth about $25,000. Elevation Wealth Partners LLC raised its position in shares of STERIS by 1,130.0% during the second quarter. Elevation Wealth Partners LLC now owns 123 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 113 shares during the last quarter. Trust Co. of Vermont acquired a new position in shares of STERIS during the second quarter valued at about $41,000. Finally, Community Financial Services Group LLC lifted its stake in shares of STERIS by 50.0% in the third quarter. Community Financial Services Group LLC now owns 216 shares of the medical equipment provider’s stock valued at $45,000 after buying an additional 72 shares during the period. Institutional investors own 94.69% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Morgan Stanley raised shares of STERIS from an “overweight” rating to a “buy” rating in a research report on Friday. Piper Sandler reaffirmed an “overweight” rating and issued a $275.00 price target (up from $270.00) on shares of STERIS in a research report on Friday, August 7th. Wall Street Zen lowered STERIS from a “strong-buy” rating to a “buy” rating in a research note on Sunday, October 11th. UBS Group cut their price objective on STERIS from $275.00 to $270.00 and set a “buy” rating for the company in a research report on Friday, August 7th. Finally, KeyCorp increased their target price on STERIS from $269.00 to $284.00 and gave the company an “overweight” rating in a research note on Friday, November 6th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, STERIS has an average rating of “Moderate Buy” and an average target price of $276.33.

STERIS Company Profile

STERIS plc (NYSE: STE) provides infection prevention and procedural products and services for healthcare, pharmaceutical, research, and other industries. Its offerings include sterilizers, washers and other equipment used to clean and sterilize medical devices and surgical instruments, as well as products for operating rooms and endoscopy procedures. The company also provides equipment installation, maintenance, repair, and training, along with contract sterilization and laboratory testing services.